文献速递湿疹皮炎与荨麻疹

慢性自发性荨麻疹中自体血清皮肤试验反应与异体细胞反应不同

Autologous serum skin test reactions in chronic spontaneous urticaria differ from heterologous cell reactions.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2021-03-02

该研究分析已发表的慢性自发性荨麻疹(CSU)研究中自体血清皮肤试验(ASST)与嗜碱性粒细胞试验(BTs)的不匹配率,并检测48例CSU患者的血清。发现约三分之一的CSU患者ASST与BTs结果不一致,且不匹配不能由嗜碱性粒细胞试验类型、异体细胞类型(嗜碱性粒细胞vs肥大细胞)或实验设置(体外vs原位)解释。

要点

  • 已发表CSU研究中ASST/BT不匹配率为31%(ASST+/BT- 22%,ASST-/BT+ 9%)。
  • 本组患者ASST/BHRA不匹配率35.4%,ASST/BAT不匹配率31.3%,两种BT显著相关(P=0.0002)。
  • 不匹配不能由嗜碱性粒细胞试验选择、异体细胞类型或实验设置解释,提示自体皮肤信号参与。

核心结论

  • 约三分之一的CSU患者ASST与嗜碱性粒细胞试验结果不一致。
  • 不匹配不能由嗜碱性粒细胞试验类型、异体细胞类型或实验设置解释,提示血清诱导的风团涉及自体皮肤信号调节肥大细胞脱颗粒。

研究设计与样本

  • 分析已发表CSU研究中ASST与BTs的不匹配率。
  • 检测48例CSU患者的血清,进行ASST、两种BTs(BHRA和BAT)、肥大细胞组胺释放试验(MCHRA)和离体皮肤微透析(SMD)。

主要发现

  • 已发表CSU研究中ASST/BT不匹配率为31%(ASST+/BT-:22%,ASST-/BT+:9%)。
  • 本组患者ASST/BHRA不匹配率35.4%(ASST+/BHRA-:18.8%,ASST-/BHRA+:16.7%),ASST/BAT不匹配率31.3%(ASST+/BAT-:6.3%,ASST-/BAT+:25.0%),两种BT显著相关(P=0.0002)。
  • 使用异体肥大细胞(体外和原位)产生类似结果:MCHRA不匹配率47.9%(ASST+/MCHRA-:18.8%,ASST-/MCHRA+:29.2%),SMD不匹配率40.0%(ASST+/SMD-:10.0%,ASST-/SMD+:30.0%),MCHRA与SMD结果高度相关(P=0.0002)。

临床怎么用

  • 临床解读ASST和BTs结果时需注意约三分之一患者存在不匹配,不应仅凭单一试验排除自身免疫性CSU。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Autoimmune chronic spontaneous urticaria (CSU) is due to mast cell (MC)-activating autoantibodies, which are screened for by the autologous serum skin test (ASST) and basophil tests (BTs). Many CSU patients are positive in only one of these tests. How often this occurs and why is currently unknown. OBJECTIVES: To characterize the prevalence of mismatched ASST and BTs in CSU patients, and to investigate possible reasons for these mismatches. METHODS: We determined the rates of ASST+/BT- and ASST-/BT+ mismatches in published CSU studies. We assessed sera from 48 CSU patients by ASST, two BTs (basophil histamine release assay, BHRA; basophil activation test, BAT), a MC histamine release assay (MCHRA) and by ex vivo skin microdialysis (SMD). RESULTS: The ASST/BT mismatch rate in published CSU studies was 31% (ASST+/BT-: 22%, ASST-/BT+: 9%). In our patients, the ASST/BHRA and ASST/BAT mismatch rate was 35.4% (ASST+/BHRA-: 18.8% and ASST-/BHRA+: 16.7%) and 31.3% (ASST+/BAT-: 6.3% and ASST-/BAT+: 25.0%), respectively, and the two BTs were significantly correlated (P = 0.0002). The use of heterologous MCs, in vitro and in situ, instead of basophils produced similar results (MCHRA mismatch: 47.9%, ASST+/MCHRA-: 18.8%, ASST-/MCHRA+: 29.2%; SMD mismatch: 40.0%, ASST+/SMD-: 10.0% and ASST-/SMD+: 30.0%), and the MCHRA was highly correlated with SMD results (P = 0.0002). CONCLUSIONS: The ASST and BTs show divergent results in a third of CSU patients. Mismatches cannot be explained by the choice of basophil assay, the type of heterologous cells exposed to CSU serum in vitro (basophils vs. mast cells), nor the experimental setting of heterologous skin mast cells (in vitro vs. in situ). Thus, serum-induced whealing, in CSU patients, seems to involve autologous skin signals modulating MC degranulation.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Baumann K, Marcelino J, Skov PS, et al. Autologous serum skin test reactions in chronic spontaneous urticaria differ from heterologous cell reactions. J Eur Acad Dermatol Venereol. 2021. PMID: 33475206. doi:10.1111/jdv.17131

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。